



HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

LLW

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY and CHANGE OF CORRESPONDENCE ADDRESS	Application/Patent Number	10/617,847
	Filing/Issue Date	July 10, 2003
	First Named Inventor/Patentee	Hazel Judith Bardsley
	Confirmation Number	7988
	Group Art Unit	1617
	Examiner Name	Layla Soroush
	Attorney Docket Number	3506.1023-000
Title	New Therapeutic Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine	
I hereby revoke all previous powers of attorney given in the above-identified application.		
<input type="checkbox"/> I hereby appoint the following practitioner(s): _____		
OR		
<input checked="" type="checkbox"/> I hereby appoint the practitioners associated with the Customer Number: 021005		
Please change the correspondence address for the above-identified application to:		
<input checked="" type="checkbox"/> Customer Number 021005 Hamilton, Brook, Smith & Reynolds, P.C. 530 Virginia Road P.O. Box 9133 Concord, Massachusetts 01742-9133		
<input type="checkbox"/> Other _____		
Please direct all telephone calls and facsimiles to:		
Name <u>Susan M. Abelleira, Esq.</u> Tel. No. <u>978-341-0036</u> Fax No. <u>978-341-0136</u>		
I am the:		
<input type="checkbox"/> Applicant/Inventor.		
<input checked="" type="checkbox"/> Authorized representative of the Assignee, Dynogen Pharmaceuticals, Inc., of the entire interest. See 37 CFR § 3.71. A Statement under 37 CFR § 3.73(b) is enclosed.		
<input type="checkbox"/> Authorized representative of the Assignee, [FILL IN WITH NAME OF ASSIGNEE], together with [FILL IN WITH NAME OF ASSIGNEE], of the entire interest. A Statement under 37 CFR § 3.73(b) is enclosed.		
SIGNATURE of Applicant or Assignee of Record		
Signature	<u>Mark F. Bosha</u>	
Name & Title	Mark F. Bosha, V.P. Legal Affairs and Chief Patent Counsel	
Date	<u>Feb. 25, 2008</u>	

STATEMENT UNDER 37 CFR § 3.73(b)Applicant/Patentee: Hazel Judith Bardsley, David Cavalla and Robert William GristwoodApplication No./Patent No.: 10/617,847 Filed/Issue Date: July 10, 2003For: New Therapeutic Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine

Dynogen Pharmaceuticals, Inc., a Corporation
(Name of Assignee) Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is

- A. ☒ the assignee of the entire right, title and interest in the patent application identified above; or
- B. ☐ an assignee together with [] of the entire right, title and interest in the patent application identified above.

The right, title and interest of the above-named assignee in the patent application identified above is established by virtue of:

- A. ☐ An assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel [], Frame [], or a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventors of the patent application identified above, to the current assignee as shown below:

1. From: Hazel Judith Bardsley, David Cavalla and Robert William Gristwood
To: Arachnova Therapeutics Ltd.
The document was recorded in the United States Patent and Trademark Office at
Reel 014642, Frames 0922-0923, or a copy thereof is attached.
2. From: Arachnova Therapeutics Limited To: Dynogen Pharmaceuticals, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 020409, Frame 0077-0085, or a copy thereof is attached.
3. From: [] To: []
The document was recorded in the United States Patent and Trademark Office at
Reel [], Frame [], or a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Signature Mark F. BosharName: Mark F. BosharTitle: V.P. Legal Affairs and Chief Patent CounselDate: Feb. 25, 2008